Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)
Event: Heart Failure 2023
Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease
Session: Cardiac amyloidosis from epidemiology to treatment
